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Abstract 
Introduction: Nausea and vomiting are the most common complications after minor head trauma that increases 
the risk of intracranial pressure rising. Therefore, the present study was aimed to compare the antiemetic effects 
of metoclopramide and ondansetron in the treatment of post-traumatic nausea and vomiting. Methods: The study 
was a controlled, randomized, double blind clinical trial, which was conducted in the first 6 months of 2014 in 
emergency department Al-Zahra and Kashani Hospitals in Isfahan, Iran. The patients with minor head trauma as-
sociated with nausea and vomiting were randomly divided into 2 groups: treatment with metoclopramide 
(10mg/2ml, slow injection) and treatment with ondansetron (4mg/2ml, slow injection). The comparison between 
the 2 groups was done regarding antiemetic efficacy and side effects using SPSS 21 statistical software. Results: 
120 patients with minor head trauma were distributed and studied into two groups of 60 patients (mean age 
35.6±14.1 years; 50.0% male). Administration of both ondansetron and metoclopramide significantly reduced the 
severity of nausea (P<0.001). Changes in the severity of nausea in both groups before and after the treatment re-
vealed that nausea had been decreased significantly in both groups (P < 0.001). The incidence of fatigue (p=0.44), 
headache (p=0.58) and dystonia (p=0.06) had no significant difference in the two groups but the incidence of 
drowsiness and anxiety in the metoclopramide group was significantly higher (P < 0.001). Conclusion: The present 
study indicated that the treatment effectiveness of ondansetron and metoclopramide are similar. However, inci-
dence of drowsiness and anxiety in the metoclopramide was considerably higher. Since these complications can 
have adverse effects on the treatment of patients with brain injury, it is suggested that it may be better to use 
ondansetron in these patients.  
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Introduction: 
n general, brain injury can occur due to sudden and 
severe head strike to a hard object, which can be 
mild, moderate or severe (1). The main causes of 
head injury include traffic accidents, falling from heights, 
physical violence, accidents at work, inside home acci-
dents and during exercise incidents. However, the most 
important cause of head trauma in Iranian population is 
traffic accident (2). Among the warning signs of head 
trauma are nausea, vomiting, dizziness, headache, 
blurred vision, and loss of balance, difficulty in sleeping, 
memory problems, tinnitus and fatigue (3). Nausea and 
vomiting are the most common complications after mi-
nor head trauma that in addition to severe harassment 
of patients increases the risk of aspiration and intracra-
nial pressure rising. Ondansetron and metoclopramide 
are two available antiemetic agents in the emergency de-
partment. Ondansetron is a serotonin 5-HT3 receptor 
antagonist, which connects to the peripheral and central 
receptors of serotonin (1). This drug is mostly used in 
nausea and vomiting after chemotherapy and surgery 
(2). It does not have any effect on dopamine receptors 
thus; it does not have extra pyramidal effect (3). Its max-
imum effect is in intravenous administration right after 
the injection. This drug has a half-life of 2-7 hours and is 
metabolized in the liver where it changes into Glucu-
ronide and sulfate which is inactive. Its most common 
side effects include headaches, fatigue, diarrhea, consti-
pation, dizziness and anxiety. The recommended dose 
for the treatment of nausea and vomiting is 4-8 milli-
grams (4, 5). Metoclopramide as an old antiemetic is 
mostly used in high doses, before chemotherapy and for 
I 
 
 This open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 
3.0). Copyright © 2015 Shahid Beheshti University of Medical Sciences. All rights reserved. Downloaded from: www.jemerg.com 
 
Zamani et al 138 
nausea and vomiting caused by various reasons (6-8). 
This drug blocks the dopamine receptors on the periph-
eral and central dopamine receptors and increases the 
movement of the upper gastrointestinal tract without in-
creasing secretion (9, 10). Its intravenous absorption 
takes about 3 minutes and the peak of its effect is about 
15 minute. This drug is metabolized in the liver and its 
half-life is approximately 4-5 hours (11). Its most com-
mon side effects include dystonia < 10%, fatigue, drows-
iness, and flushing. Based on the above-mentioned rea-
sons, the present study was aimed to compare the antie-
metic effects of metoclopramide and ondansetron in the 
treatment of post head trauma nausea and vomiting. 
Methods: 
Study design and setting 
The study was a controlled, randomized, double blind 
clinical trial, which was conducted in the first 6 months 
of 2014 in Al-Zahra and Kashani Hospitals in Isfahan, 
Iran. The present study was supervised and accepted by 
the ethics committee of Isfahan University of Medical 
Sciences. All the participants have consciously signed a 
written consent before entering the study. The study was 
registered in Iranian registry of clinical trial (IRCT num-
ber: IRCT2015043012072N6).  
Participants 
The studied population included patients with minor head 
trauma associated with nausea and vomiting who were 
referred to the emergency department . Minor head 
trauma has been considered as GCS 14-15.  The patients 
older than 15 years old, with minor head trauma, nausea 
and vomiting, and a triage level of 3 or higher based on 
emergency severity score were included. The exclusion 
criteria were considered as follow: hemodynamic insta-
bility; pregnancy/lactation; any neurologic deficit; rest-
less leg syndrome; alcohol usage; consumption of any an-
tiemetic drugs during the 8 hours prior to admission; pre-
vious administration of intravenous fluids; motion/ver-
tigo related nausea and vomiting; chemotherapy or radio-
therapy; inability to complete and understand study ex-
planations or outcome measures; finally allergy or previ-
ous adverse reactions to metoclopramide or ondansetron; 
and lack of data regarding demographic data and the se-
verity of nausea and vomiting based on the visual analog 
scale (VAS). The qualified patients then entered the study 
using convenience sampling. Permuted-block randomiza-
tion was done with a bock size of 6. 
Intervention 
The patients were randomly divided into 2 groups: treat-
ment with metoclopramide (10mg/2ml, slow injection) 
and treatment with ondansetron (4mg/2ml, slow injec-
tion). Preparing the drugs was done by an independent 
pharmacologist in a sterilized manner. For the study to 
be double –blind, the drugs were packed in nameless sy-
ringes, and in numbered, dark packs and only the main 
researcher knew about the drug content. The drugs were 
kept in a fridge in the emergency department. The pa-
tients and the other researchers were blind to the drug 
content and the treatment group. Drug information and 
treatment group of the patients would only be revealed 
if the patients showed extrapyramidal side effects of the 
drugs, which did not happen in this study. Drug admin-
istration and patient assessment was done by emer-
gency medicine residents. 20 minutes post drug admin-
istration, nausea level was measured again. If the sever-
ity of nausea had not decreased at least by 20 mm com-
pared to the rate before the treatment intervention, a 
rescue dose (4mg ondansetron) would be prescribed for 
the patient. 
Measurements 
Nausea severity was measured using self-rated visual 
analogue scale (VAS) before and 20 minutes after the in-
tervention. VAS was a standard 100 mm (mm) method 
on which the left side indicated no nausea and the right 
side was an indicator of the worst nausea possible. Using 
this scale for assessing nausea severity was accepted in 
previous studies. According to these studies the mini-
mum difference in nausea severity counted as clinically 
significant, was set at 20 mm. Nausea severity was di-
vided into 3 levels: severe nausea (VAS > 70 mm), mod-
erate nausea (50 mm < VAS <70 mm) and mild nausea 
(VAS < 50 mm). 
Outcomes 
The primary outcome was defined as mean nausea se-
verity according to VAS in the twentieth minute post 
drug administration. Secondary outcomes included 
needing a rescue dose and side effects of the drugs.  
Statistical analysis 
Population sample size for each group was determined 
based on comparing mean nausea severity between the 
2 treatment groups. Based on previous studies (12), 
mean and standard deviation of nausea severity reduc-
tion before and after ondansetron administration was 40 
mm and 24 mm respectively. Based on this, by consider-
ing α = 0.05 and 90% power (β = 0.1), the sample size of 
43 patients in each group was sufficient. Finally, 60 pa-
tients were included in each group. The data were ana-
lyzed using SPSS 21.0. Nausea severity was expressed as 
mean and standard deviation. To compare the 2 groups, 
t-test was used and for comparing the effects of the drug 
before and after administration, paired t-test was used. 
The drug side effect was also expressed as frequency and 
percentage. The comparison between the 2 groups was 
done using the chi square, the Fisher exact, or Mann-
Whitney U test. In all the analyses, p < 0.05 was defined 
as the level of significance. 
Results: 
Finally, 120 patients with minor head trauma were dis-
tributed and studied into two groups of 60 patients 
(mean age 35.6 ± 14.1 years; 50.0% male). Mean age of 
metoclopramide and ondansetron treated groups were 
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36.1 ± 14.0 and 35.0 ± 14.2 years, respectively (p = 0.69). 
The sex distribution in ondansetron (45.0% male) and 
metoclopramide groups (55.0% male) had no significant 
difference. Administration of both ondansetron and 
metoclopramide significantly reduced the severity of 
nausea (P < 0.001). 
The average score of nausea severity before the injection 
of ondansetron and metoclopramide in the groups were 
89.3±12.5 and 85.3 ± 14.9, respectively (p = 0.11). After 
intervention, nausea in the two groups were 32.3 ± 14.8 
and 36. 5 ± 17.8, respectively (p = 0.17) (Figure 1). Be-
fore intervention 51 patients (85.0%) of the on-
dansetron group and 47 patients (78.3%) of the meto-
clopramide group had severe nausea (VAS > 70 mm) (p 
= 0.35). After intervention only 2 patients (3.3%) of the 
ondansetron treated and 5 patients (8.3%) of the meto-
clopramide treated group had severe nausea (p = 0.16).  
However, changes in the severity of nausea in both 
groups before and after the treatment revealed that nau-
sea had been decreased significantly in both groups (P < 
0.001) (Figure 2). The incidence of fatigue (p = 0.44), 
headache (p=0.58) and dystonia (p = 0.06) had no signif-
icant difference in the two groups but the incidence of 
drowsiness and anxiety in the metoclopramide group 
was significantly higher (P < 0.001) (Table 1). 2 (1.7%) 
patients needed the rescue dose which were in the meto-
clopramide treated group (p = 0.50). 
Discussion: 
The present study showed that the antiemetic effect of 
ondansetron and metoclopramide in patients with mi-
nor head trauma is the same. The frequency of severe 
nausea in the ondansetron group reduced from 85% to 
3.3% while in the metoclopramide group, reduced from 
78.3% to 8.3%. The incidence of drowsiness and anxiety 
were significantly lower in the ondansetron treated pa-
tients.  
The antiemetic effects of ondansetron and metoclo-
pramide have been compared in various studies, the re-
sults of which are in line with the current study. For in-
stance, a study by Pitts et al. reveals that the effective-
ness of ondansetron and metoclopramide compared to 
the placebo, show no significant difference in decreasing 
nausea and vomiting in the patients admitted to the 
emergency department (13). Also Egerton-Warburton et 
al. expressed in their study that the antiemetic effects of 
ondansetron and metoclopramide were no different 
compared to the placebo (14). In addition, Barrett et al. 
and Al-Ansari et al. have reported similar results (12, 
15). In the present study, mean pain relief was 48.8 mm 
in the metoclopramide group and 57.0 mm in the on-
dansetron ones which was significantly different from 
the results of the mentioned studies. In this regard, Eger-
ton-Warburton et al. showed that administering 4mg on-
dansetron and 20mg metoclopramide resulted in a 27 
mm and 28 mm decrease in nausea severity, respectively 
(2). These levels in the Barrett et al. study was 40 mm for 
ondansetron and 32 mm for metoclopramide (15). Con-
cerning the drugs’ side effects, Patanwala et al. propose 
in their review study that due to safety, ondansetron is a 
better choice for the first line of treatment for decreasing 
nausea and vomiting in the patients admitted to the 
emergency department (16). The present study also 
showed that compared to metoclopramide, ondansetron 
administration, showed less side effects. In addition, in a 
study by Egerton-Warburton et al. 6 patients showed 
side effects in the group treated with metoclopramide, 







Age (Mean ± SD) 36.1 ± 14.0 35.0 ± 14.2 0.69 
Gender    
Male 27 (45.0) 33 (55.0) 0.27 
Female 33 (55.0) 27 (45.0)  
Headache    
Yes 30 (50.0) 33 (55.0) 0.58 
No 30 (50.0) 27 (45.0)  
Drowsiness    
Yes 26 (43.3) 8 (13.3) <0.001 
No 34 (56.7) 52 (86.7)  
Fatigue    
Yes 23 (38.3) 19 (31.7) 0.44 
No 37 (61.7) 41 (68.3)  
Anxiety    
Yes 37 (61.7) 11 (18.3) <0.001 
No 23 (38.3) 49 (81.7)  
Dystonia    
Yes 5 (8.3) 0 (0.0) 0.057 
No 55 (91.7) 60 (100.0)  
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whereas only 2 showed side effects in the group treated 
with ondansetron (14). A shortcoming in the present 
study was the lack of a placebo group. If such a group was 
studied, an assessment of the placebo effect would have 
been possible. In addition, since convenience sampling 
was used, selection bias is possible. 
Conclusion: 
The present study indicated that the treatment effective-
ness of ondansetron and metoclopramide are similar. 
However, incidence of drowsiness and anxiety in the 
metoclopramide was considerably higher. Since these 
complications can have adverse effects on the treatment 
of patients with brain injury, it is suggested that it may 
be better to use ondansetron in these patients. 
Findings. 
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Figure 1: Mean changes of nausea severity before and after 
intervention in the 2 groups 
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